HealthCare Royalty Partners (“HCR”) is a private investment firm that purchases royalties and uses debt-like structures to invest in commercial or near-commercial stage biopharmaceutical assets. They target healthcare assets with significant clinical value and strong barriers to entry that are meaningful to their marketer. They also look for assets that will produce sustainable revenues over an extended period of time. Their investments span the pharmaceutical, biotechnology, and specialty pharmaceuticals sectors.

Investment Management

HealthCare Royalty Partners

Clarke B. Futch

Aaron B. Simon

Joshua C. House

Tolly Flinn

Hayden C.B. Futch

Collin G. Stewart

Timothy R.M. Bryant

Christopher A. White

Lauren C. Jorgensen

John A. Urquhart

Shin W. Kang

Warren D. Cooper

Carlos M. Almodóvar

Anthony G. Rapsomanikis

Spencer H. Schneider

Michele D. Romaniello

Rosa I. Mercado

Stephanie A. Gilbey

Thomas K. Conner

The Business Development and Strategy team at HealthCare Royalty Partners is responsible for identifying and evaluating potential investment opportunities in the biopharmaceutical sector. They focus on developing strategic partnerships, negotiating transactions, and formulating growth strategies that align with the company’s investment goals. This team leverages their expertise to ensure that HCR acquires assets with significant clinical value and strong market positioning, ultimately driving sustainable revenue growth.

Business Development and Strategy

Leadership Team

Finance and Accounting

Business Development and Strategy

About

Team members

Other teams at HealthCare Royalty Partners

Leadership Team

Finance and Accounting